Cholesterol and glucose profiles according to different fasting C-peptide levels: a cross-sectional analysis in a healthy cohort from the Czech Republic.
Atherogenic index
C-peptide
Cholesterol
HDL
LDL
Lipoprotein
Journal
Journal of applied biomedicine
ISSN: 1214-0287
Titre abrégé: J Appl Biomed
Pays: Poland
ID NLM: 101221755
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
01
02
2021
accepted:
24
09
2021
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
11
5
2022
Statut:
ppublish
Résumé
The relationship between glycaemia and lipoprotein metabolism has not been completely clarified, and slight differences may be found between local authors, trials and evaluated parameters. Therefore this cross-sectional study investigated fasting cholesterol and glucose levels along with the determination of atherogenic index in a cohort of healthy individuals from the Czech Republic in relation to their fasting C-peptide levels. Data were collected between 2009 and 2018 and a total of 3189 individuals were stratified by C-peptide reference range (260-1730 pmol/l) into three groups - below (n = 111), within (n = 2952) and above (n = 126). Total, HDL, LDL cholesterol and atherogenic index were used to compare lipoprotein levels by relevant C-peptide concentrations. Participants using the supplements to affect lipid or glycaemia metabolism were excluded from this study. The evaluation of blood parameters in a fasting state included correlations between C-peptide and cholesterols, differences of variances (F-test) and the comparison of lipoprotein mean values (t-test) between the groups created by the C-peptide reference range. Mean values of total (4.9, 5.1, 5.3 mmol/l), LDL (2.6, 3.1, 3.4 mmol/l) cholesterol and atherogenic index (2.1, 2.8, 3.7) were higher with increasing C-peptide levels, whereas HDL was inversely associated with fasting C-peptide concentration. A positive and negative correlation between atherogenic index (rxy = 0.36) and HDL level (rxy = -0.36) with C-peptide values was found. Differences of HDL, LDL and atherogenic index were, in particular, recorded between the groups below and above the reference range of C-peptide (p ≤ 0.001). Considerable differences (p ≤ 0.001) were also observed for the same lipoprotein characteristics between the groups above and within the C-peptide reference. Generally, the type of cholesterol is crucial for the evaluation of specific changes concerning the C-peptide range. Lipoprotein concentrations differ in relation to C-peptide - not only below and above the physiological range, but also inside and outside of it. Conclusions: Fasting levels of cholesterol, plasma glucose, and atherogenic index were strongly associated with fasting C-peptide levels in healthy individuals. Our data suggest that fasting C-peptide could serve as a biomarker for the early detection of metabolic syndrome and/or insulin resistance prior to the manifestation of type 2 diabetes.
Identifiants
pubmed: 34907741
doi: 10.32725/jab.2021.023
doi:
Substances chimiques
Blood Glucose
0
C-Peptide
0
Cholesterol, HDL
0
Lipoproteins
0
Cholesterol
97C5T2UQ7J
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
220-227Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Andrade RLM, Gigante DP, de Oliveira IO, Horta BL (2018). C-Peptide and cardiovascular risk factors among young adults in a southern Brazilian Cohort. BMC Endocr Disord 18: 80. DOI: 10.1186/s12902-018-0308-5.
pubmed: 30400868
doi: 10.1186/s12902-018-0308-5
Bo S, Gentile L, Castiglione A, Prandi V, Canil S, Ghigo E, Giccone G (2012). C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up. Eur J Endocrinol 167(2): 173-180. DOI: 10.1530/EJE-12-0085.
pubmed: 22577110
doi: 10.1530/EJE-12-0085
Díaz-Ruiz M, Martínez-Triguero ML, López-Ruiz A, Fernández-de la Cruz F, Bañuls C, Hernández-Mijares A (2019). Metabolic disorders and inflammation are associated with familial combined hyperlipemia. Clin Chim Acta 490: 194-199. DOI: 10.1016/j.cca.2018.09.009.
pubmed: 30201373
doi: 10.1016/j.cca.2018.09.009
Friedecký B, Kratochvíla J, Springer D, Prázný M, Pelikánová T, Zima T, Racek J (2016). Diabetes mellitus - laboratorní diagnostika a sledování stavu pacientů [Diabetes mellitus - laboratory diagnosis and monitoring of patients]. Klin Biochem Metab 24: 32-47.
Garcia-Webb P, Bonser AM, Whiting D, Masarei JRL (1983). Insulin resistance a risk factor for coronary heart disease? Scan J Clin Lab Invest 43(8): 677-685. DOI: 10.1080/00365518309168849.
doi: 10.1080/00365518309168849
Ghorbani A, Shafiee-Nick R (2015). Pathological consequences of C-peptide deficiency in insulin-dependent diabetes mellitus. World J Diabetes 6(1): 145-150. DOI:10.4239/wjd.v6.i1.145.
pubmed: 25685285
doi: 10.4239/wjd.v6.i1.145
Harnishsingh B, Rama B (2018). Is C-peptide a predictor of severity of coronary artery disease in metabolic syndrome? An observational study. Indian Heart J 70(Suppl. 3): S105-S109. DOI: 10.1016/j.ihj.2018.07.005.
pubmed: 30595240
doi: 10.1016/j.ihj.2018.07.005
Hirai FE, Moss SE, Klein BE, Klein R (2008). Relationship of glycemic control, exogenous insulin and C-peptide levels to ischemic heart disease mortality over a 16-year period in people with older-onset diabetes. Diabetes Care 31(3): 493-497. DOI: 10.2337/dc07-1161.
pubmed: 18025409
doi: 10.2337/dc07-1161
Horáková D, Štěpánek L, Janout V, Janoutová J, Pastucha D, Kollárová H, et al. (2019). Optimal homeostasis model assessment of insulin resistance (HOMA-IR) cut off in Czech population. Medicina (Kaunas) 55(5): 158. DOI: 10.3390/medicina55050158.
pubmed: 31108989
doi: 10.3390/medicina55050158
Jones AG, Hattersley AT (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30(7): 803-817. DOI: 10.1111/dme.12159.
pubmed: 23413806
doi: 10.1111/dme.12159
Karen I, Svačina Š, et al. (2014). Diabetes mellitus v primární péči [Diabetes mellitus in primary care], 2nd ed. Prague: Axonite.
Khan HA, Sobki SH, Ekhzaimy A, Khan I, Almusawi MA (2018). Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals. Saudi J Biol Sci 25(8): 1729-1732. DOI: 10.1016/j.sjbs.2018.05.027.
pubmed: 30591792
doi: 10.1016/j.sjbs.2018.05.027
Kulkarni CM, Patil S (2016). Urinary C-peptide and urine C-peptide/creatinine ratio (UCPCR) are possible predictors of endogenous insulin secretion in T2DM subjects - a randomized study. Int J Pharm Bio Sci 7: 443-446. DOI: 10.22376/ijpbs.2016.7.4.b443-446.
doi: 10.22376/ijpbs.2016.7.4.b443-446
Leighton E, Sainsbury CA, Jones GC (2017). A Practical review of C-Peptide testing in diabetes. Diabetes Ther 8(3): 475-487. DOI: 10.1007/s13300-017-0265-4.
pubmed: 28484968
doi: 10.1007/s13300-017-0265-4
Li Y, Li Y, Meng L, Zheng L (2015). Association between serum C-peptide as a risk factor for cardiovascular disease and high-density lipoprotein cholesterol levels in nondiabetic individuals. PLoS One 10(1): e112281. DOI: 10.1371/journal.pone.0112281.
pubmed: 25559358
doi: 10.1371/journal.pone.0112281
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7): 412-419. DOI: 10.1007/BF00280883.
pubmed: 3899825
doi: 10.1007/BF00280883
Methodology of C-peptide, glucose, total, HDL and LDL cholesterol (2020). Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové. [online] [cit. 2020-07-15]. Available at: http://ukbd.fnhk.cz/seznam-metod.html
Min J-Y, Min K-B (2013). Serum C-peptide levels and risk of death among adults without diabetes mellitus. Can Med Assoc J 185(9): E402-408. DOI: 10.1503/cmaj.121950.
pubmed: 23589428
doi: 10.1503/cmaj.121950
Patel N, Taveira TH, Choudhary G, Whitlatch H, Wu W-C (2012). Fasting serum C-peptide levels predict cardiovascular and overall death in nondiabetic adults. J Am Heart Assoc 1(6): e003152. DOI: 10.1161/JAHA.112.003152.
pubmed: 23316320
doi: 10.1161/JAHA.112.003152
Pickens CA, Matsuo KH, Fenton JI (2016). Relationship between body mass index, C-Peptide, and delta-5-desaturase enzyme activity estimates in adult males. PLoS One 11(3): e0149305. DOI: 10.1371/journal.pone.0149305.
pubmed: 27023786
doi: 10.1371/journal.pone.0149305
Pozzan R, Dimetz T, Gazzola HM, Gomes MB (1997). The C-peptide response to a standard mixed meal in a group of Brazilian type 1 diabetic patients. Braz J Med Biol Res 30(10): 1169-1174. DOI: 10.1590/S0100-879X1997001000005.
pubmed: 9496433
doi: 10.1590/S0100-879X1997001000005
Rebsomen L, Khammar A, Raccah D, Tsimaratos M (2008). C-peptide effects on renal physiology and diabetes. Exp Diabetes Res 2008: 281536. DOI: 10.1155/2008/281536.
pubmed: 18509500
doi: 10.1155/2008/281536
Wahab N, Chen R, Curb JD, Bradley J, Willcox BJ, Rodriguez BL (2018). The association of fasting glucose, insulin and C-peptide with 19-year incidence of coronary heart disease in older Japanese-American men; the Honolulu Heart Program. Geriatrics (Basel) 3(2): 22. DOI: 10.3390/geriatrics3020022.
pubmed: 30555835
doi: 10.3390/geriatrics3020022
Walton C, Lees B, Crook D, Godsland IF, Stevenson JC (1995). Relationships between insulin metabolism, serum lipid profile, body fat distribution and blood pressure in healthy men. Atherosclerosis 118(1): 35-43. DOI: 10.1016/0021-9150(95)05590-s.
pubmed: 8579629
doi: 10.1016/0021-9150(95)05590-s
Yosten GLC, Maric-Bilkan C, Luppi P, Wahren, J (2014). Physiological effects and therapeutic potential of proinsulin C-peptide. Am J Physiol Endocrinol Metab 307(11): 955-968. DOI: 10.1152/ajpendo.00130.2014.
pubmed: 25249503
doi: 10.1152/ajpendo.00130.2014
Zvára K, Štěpán J (2002). Pravděpodobnost a matematická statistika [The probability and mathematical statistics], 3rd ed. Prague: Matfyzpress.